GlaxoSmithKline to Pay $105 Million to Settle Deceptive Ad Charge

GlaxoSmithKline to Pay $105 Million to Settle Deceptive Ad Charge
June 4th, 2014

GlaxoSmithKline will pay $105 million to settle charges brought by a group of state Attorneys General arising from alleged improper marketing and promotion of the asthma drug Advair and the anti-depressant drugs Paxil and Wellbutrin.

The New York Attorney General’s settlement relating to Paxil builds on a 2006 New York settlement in which GSK agreed to post summaries of clinical studies and establish and maintain a Clinical Trial Register, an official platform and catalogue for registering clinical trials.

GSK was represented by Matthew O’Connor of Covington & Burling in Washington, D.C.

“When pharmaceutical companies advertise drugs to consumers, their claims should be backed by the best available science, not just slick marketing,” said Attorney General Eric Schneiderman. “Medical decisions are among the most personal and important decisions an individual makes, and drug companies should be held accountable for misleading claims made in advertising. New Yorkers should be able to trust that ads for prescription medications are medically accurate.”

The Attorneys General alleged that GSK engaged in deceptive and misleading practices when it marketed Advair, Paxil, and Wellbutrin for off-label uses and concealed risks associated with Paxil. ...

STORY CONTINUES

http://www.corporatecrimereporter.com/news/200/glaxosmithklein-to-pay-105-million-to-settle-deceptive-ad-charge/

Comments are closed.